Such an approach could be more specific for Alzheimer's than symptoms-based diagnoses while also allowing for earlier detection and treatment of the condition.
The grant was awarded through the Alzheimer's Drug Discovery Foundation's Diagnostic Accelerator, a partnership between the charity and philanthropic partners.
The agreement gives Quanterix an opportunity to explore the clinical utility of its Nf-l marker without having to move its instruments into the clinical space.
A combination of three biomarkers accurately predicted abnormal accumulation of beta-amyloid plaques in the brains of living Alzheimer's disease patients.
The researchers developed a plasma protein signature that can identify patients with cerebrospinal fluid amyloid-β42 levels indicative of risk for the disease.
The study is part of a broader effort by academic and industry researchers to develop blood-based tests for easier, less expensive Alzheimer's screening.
According to researchers, measurement of serum neurofilament light chain levels could aid in early diagnosis and monitoring of the progression of disease.
